Fred Brown Knihy

"In [this book], the authors use extensive interviews with [snake handlers] to tell the stories of three of the most prominent snake-handling families."--Back cover

Focusing on the historical markers of East Tennessee, the book explores the region's rich cultural and historical tapestry through significant personalities and events. Fred Brown chronicles his journey to uncover the stories behind these markers, which span from prehistoric times to the Civil War and beyond, including contributions from Native Americans and notable figures in various wars. The narrative also delves into the region's unique political history, highlighting conflicts and movements, making it an engaging exploration of East Tennessee's diverse heritage.

This book contains the proceedings of the International Symposium on Pertussis Vaccine Trials, held in Rome in October 1995. The meeting was organized following the almost simultaneous release of the results of five clinical trials and two other clinical studies of acellular pertussis vaccines. These large, multi-centre studies, conducted independently and over several years, explored the efficacy, safety, and immuno-genicity of several acellular pertussis vaccines, comparing them with whole-cell vaccine and/or placebo. In addition, the book covers other major topics concerning the use of acellular and whole-cell pertussis vaccines, including basic biological and epidemiological questions, various considerations in interpreting the studies' results, regulatory issues, and worldwide perspectives on the expanded use of acellular vaccines.Bringing together the world's leading experts in this field of research and summarizing all the major aspects of pertussis prevention and control, this book is a vital reference for paediatricians, public health officials, microbiologists, immunologists, epidemiologists and all biomedical scientists who produce or regulate the use of vaccines.

Stepping through time to past and present communities, settled in deep hollows and surrounded by ridges and mountains in Tennessee's Appalachia, is to confront a different and disappearing realm. Travel along Hogskin and Richland Valleys. Visit Frenches Mill and Dulaney General Store while passing cantilever barns, one-room school buildings and steepled churches. Listen as octogenarians Robert, Charles, Glenn and others explain life without electricity. Former Cades Cove residents Lois and Inez tell stories of living in the Great Smoky Mountains National Park before it was a national park. Authors Fred Brown, retired journalist, and Harry Moore, retired geologist, explore Tennessee's Appalachian region, recalling its culture, land and people before it vanishes into the abyss of time.

Focusing on positivity and mindfulness, this book encourages readers to reflect on uplifting thoughts and ideals. It aims to inspire hope in a world often filled with despair, promoting the importance of meditating on good and lovely aspects of life. Through its themes, it seeks to guide individuals towards a more optimistic perspective, fostering resilience in society.

This monograph contains the proceedings of a conference devoted to progress and emerging issues in therapeutic cancer vaccine development since the 1998 FDA/NCI workshop. The emphasis is on progress in the clinical trials of cancer vaccines in late-stage development, but the volume also includes presentations and discussions on exciting earlier-stage products as well as updates on regulatory positions in the USA, Canada, Europe, and Australia. Session I concentrates on regulatory considerations in cancer vaccine development, including a round table of regulatory agency representatives from North America, Europe, and Australia. Session II continues with a consideration of several different types of cancer vaccines, including whole cells, cell lysates, multivalent recombinants and peptides. Session III highlights dendritic cell vaccines and dendritic cells fused to tumour cell vaccines. Session IV focuses on preventive cancer vaccines for cervical carcinoma and liver cancer and various aspects of the immune response to cancer vaccines.

For some 30 years it has been a rule of thumb that antibody to influenza haemagglutinin, induced by natural infection or vaccination, is a universal and useful marker of immunity to influenza. It now seems important to re-examine this hypothesis. Knowledge of the mechanisms of acquired influenza immunity and correlations with measurable laboratory parameters is clearly of importance in understanding influenza epidemiology and vaccine-induced immunity. While immunity is certainly multi-factorial, involving both B and T cell responses, any comprehensive assessment is complicated by the capacity of the virus to undergo extensive and frequent antigenic variation. The aim of this workshop was

Attempting to develop better vaccines This monograph contains proceedings from an International Symposium on Vaccines for OIE List A and Emerging Animal Diseases held in Ames, Iowa, USA, in September 2002. The purpose of the meeting was to review the availability, safety and efficacy of veterinary vaccines for OIE List A diseases and for selected emerging animal diseases. An objective of the meeting was to gather information on the suitability of vaccines for use as an aid in controlling an outbreak in a previously disease-free country. Information on current vaccines and research on vaccines under development was presented. The role of the World Organization for Animal Health (OIE) in setting standards for control of animal diseases was reviewed as well as regulatory considerations for emergency use of vaccines in the USA and EU. A survey of the worldwide availability of vaccines for OIE list A diseases was presented and experiences in using vaccines for controlling transboundary animal diseases were discussed. This volume will be of special interest to animal health researchers in university, government, or commercial settings attempting to develop better vaccines for these important diseases.

Regulatory documents and inspections have put increasing emphasis on process validation for all types of products, including biological and biotechnological ones. Until now, no description of a process validation for complex biological processes exists, let alone any concrete suggestion how to attain this book, however, attempts to fill the gap. Taking the current state of scientific practice in process validation as a starting point, this volume portrays the expectations of the regulatory community and provides detailed examples of how various types of biological and biotechnological processes could be validated. Considering the sizeable difficulties in designing a single method of process validation suitable for all types of processes and products, the authors discuss the implications and present many possible routes to a successful validation process.

Immune responses to biological products have occurred with many approved therapeutics. The proportion of patients mounting an immune response is product dependent and the clinical significance of the immune response also varies with the nature of the product. Some products can induce production of significant levels of antibodies without any detectable effect on the activity of the product. However, neutralizing antibodies can attenuate the efficacy of the treatment and significant adverse clinical events can be seen if neutralizing antibodies cross-react with patients' endogenous proteins. Prediction of immunogenicity includes the use of bio-informatics to predict T-cell epitopes, T-cell stimulation assays and in vivo transgenic animal models. Approaches to prevent immunogenicity involve methods to design out immunogenic sequences, protein pegylation and inducing tolerance. Current methods for assessing and detecting immunogenicity include in vivo animal models, antibody assays and biological assays. The advantages and disadvantages of the various methods illustrate that a battery of tests is required to appropriately monitor patients' immune responses during clinical trials.